7
Participants
Start Date
June 27, 2018
Primary Completion Date
February 18, 2025
Study Completion Date
July 1, 2026
Bevacizumab
Given IV
Biopsy Procedure
Undergo tumor biopsy
Biospecimen Collection
Undergo blood sample collection
Computed Tomography
Undergo CT scan
Magnetic Resonance Imaging
Undergo MRI
Osimertinib
Given PO
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Moffitt Cancer Center-International Plaza, Tampa
Moffitt Cancer Center, Tampa
Ohio State University Comprehensive Cancer Center, Columbus
University of Kansas Clinical Research Center, Fairway
University of Kansas Hospital-Westwood Cancer Center, Westwood
Nebraska Medicine-Village Pointe, Omaha
Nebraska Medicine-Bellevue, Bellevue
University of Nebraska Medical Center, Omaha
University of Oklahoma Health Sciences Center, Oklahoma City
Huntsman Cancer Institute/University of Utah, Salt Lake City
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
Keck Medical Center of USC Pasadena, Pasadena
University of California Davis Comprehensive Cancer Center, Sacramento
Smilow Cancer Center/Yale-New Haven Hospital, New Haven
Yale University, New Haven
National Cancer Institute (NCI)
NIH